Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Breast Neoplasms
  • Health Care Costs
  • Paclitaxel
  • Quality of Life

abstract

  • Patients with evidence of tumor response on paclitaxel had a QoL benefit not observed in nonresponders, and this response was associated with a trend for lower overall costs.

publication date

  • September 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2002.08.057

PubMed ID

  • 12202668

Additional Document Info

start page

  • 3665

end page

  • 73

volume

  • 20

number

  • 17